Please login to the form below

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more...Read the full article: https://bit.ly/2rkI7jc


4th May 2018

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership
Infographic
Migraine market snapshot
Research Partnership
Webinar
Monitoring the impact of COVID-19 on the market access landscape
Research Partnership
Live webinar from Singapore
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Research Partnership
Guide
UX research
Research Partnership
Article: Why pharma must trust the science of behaviour

Research Partnership